Sphingolipids In Disease

Sphingolipids are lipid components of the plasma membrane of eukaryotic cells with an important function in signaling mechanisms in the cell. This book provides insight into the physiological and pathophysiological role of sphingolipids and in particular its derivative ceramide. The function of Sphingolipids in cell signaling with regard to infectious and lung diseases, cancer, cardiovascular diseases and neuropsychiatric disorders are described and treated in distinct parts. Together with Volume 215 from the same Editors, the collection represents a unique, comprehensive work on Sphingolipids, providing information on both: Sphingolipid basic biology as well as its important function in a (patho)physiological context. The book is written for scientists in pharmacology, biochemistry and cell biology with a focus on biomedical research as well as for clinicians in pharmacology, oncology, cardiology, neurology and infectious disease. ​

This book is about the various roles of bioactive ceramides and other sphingolipids in cellular biology. The enigmatic biophysical and biochemical properties of ceramides and their propensity to influence membranes whether as rafts or protein-permeable channels are heavily discussed. Metabolism of ceramides and their metabolites is also focused with ceramide synthase family of proteins being a target of extensive review. Ceramide 1-phosphate and other sphingolipids are also presented in cellular physiology and pathophysiology. Prokaryotic origins of mitochondria at the level of membranes and the occurrence of apoptosis in bacteria are presented. Many aspects of ceramide and sphingolipid biology are addressed in this book. Its focus is the metabolism of ceramide in normal and diseased states and the biophysical and biochemical mechanisms governing the bioactivity of these molecules. Sphingolipid research has surged over the past thirty years and this book gathers the recent findings of various aspects of sphingolipid biochemistry. World-renowned scientists from the field of lipid biology, specifically sphingolipid biochemistry, were gathered to write this book. Scholars from most continents of the globe committed to write diligently about their expertise and the newest findings in the relevant fields. This book came to fruition after almost a year and a half of laborious preparation and diligent writings. This book is targeted to the experienced reader who is looking to read about the various aspects of bioactive ceramide signaling, as well as to the newcomer into the field, as the topics are explained in concise yet very informative manner. The authors and editor wish all readers a pleasant time reading this volume, and are adamant that this book will meet all expectations.

Sphingolipids are lipid components of the plasma membrane of eukaryotic cells with an important function in signaling mechanisms in the cell. This book provides insight into the physiological and pathophysiological role of sphingolipids and in particular its derivative ceramide. The function of Sphingolipids in cell signaling with regard to infectious and lung diseases, cancer, cardiovascular diseases and neuropsychiatric disorders are described and treated in distinct parts. Together with Volume 215 from the same Editors, the collection represents a unique, comprehensive work on Sphingolipids, providing information on both: Sphingolipid basic biology as well as its important function in a (patho)physiological context. The book is written for scientists in pharmacology, biochemistry and cell biology with a focus on biomedical research as well as for clinicians in pharmacology, oncology, cardiology, neurology and infectious disease. ​

Inborn Disorders of Sphingolipid Metabolism is a collection of papers presented at the Third International Symposium on the Cerebral Sphingolipidoses and Allied Diseases, held at the Isaac Albert Research Institute of the Jewish Chronic Disease Hospital and at the State University of New York, Downstate Medical Center, on October 25 and 26, 1965. This book is organized into three parts encompassing 35 chapters. Part I deals first with electron microscopic, histochemical, and morphological investigations of certain sphingolipid metabolism disorders. This part also examines several case reports on the features and symptoms of spongy degeneration of the central nervous system, familial leukodystrophy, adrenal insufficiency, and cutaneous melanosis. Part II surveys the metabolism, biosynthesis, and structure of gangliosides and sialic acids. This part also considers the nature of the lipophilic portions of the brain gangliosides. This part particularly looks into the features and clinical manifestation of Tay-Sachs disease. The third part covers the genetic and clinical aspects of the Tay-Sachs disease. This part also evaluates the genetics of the Hurler-Hunter syndrome, Batten-Spielmeyer-Vogt disease, and lipogranulomatosis syndrome. This book is of value to biochemists, histochemists, geneticists, and researchers in the allied fields of lipidosis.

This book attempts to analyze the latest discoveries in sphingolipid biology and how the alteration of their metabolism leads to altered signaling events and to the development of pathobiological disorders, such as cancer, cardiovascular diseases, asthma, diabetes, inflammation and infectious diseases.

Current thinking holds that obesity derives primarily from overnutrition (though compelling arguments for other mechanisms, like endocrine disruption by environmental pollutants, also gain support from the literature). In animals, overnutrition is initially handled by adipose tissue expansion; however, exhaustion of this route of lipid sequestering results in oversupply of lipid to other tissues including skeletal muscle, heart, liver, and others. Failure of these tissues to clear excess lipids through either metabolism or sequestration into putatively inert triacylglycerols results in perturbation of bioactive lipid metabolism in cells. In particular, aberrant generation of bioactive sphingolipids is implicated in a multitude of pathological outcomes of metabolic disease including insulin resistance, inflammation, cardiomyopathy, and others. This volume addresses not only the fundamentals of sphingolipid metabolism and analysis, but also the roles of sphingolipids in these disease processes.

The Organizing Committee of the 15th International Conference on Bioactive Lipids in Cancer, Inflammation and Related Diseases compiled a group of junior investigators to provide reviews on the topics they presented at the Puerto Vallarta Bioactive Lipids conference, as part of the book series, Advances in Experimental Medicine and Biology (AEMB). The book in this series will be titled Bioactive Lipids in Cancer, Inflammation and Related Diseases. Topics range from all classes of lipids including prostaglandins, resolvins, spingolipids, P450-derived lipids, endocannabanoids and phospholipids. The focus includes physiology, cell biology, and structural studies in organisms from bacteria to humans and how these studies addressed the role of lipids in various disease i.e. cancer, inflammation, diabetes, obesity, cardiovascular disease and others.

This book provides an up-to-date review of the fundamentals of sphingolipid metabolism and its role in metabolic diseases. Focusing on the sphingolipid de novo synthesis pathway, the effect of sphingomyelin, ceramide, and sphingosine-1-phosphate, and linkage between sphingolipids and other lipids, such as cholesterol, it covers serine palmitoyltransferase, ceramide synthases, ceramidases, sphingosine kinases, and sphingomyelin synthases, and more. While highlighting how rare diseases related to abnormal glycosphingolipid metabolism, this publication introduces sphingolipid metabolism-related diseases, such as lung diseases and cancers, as well as sphingolipid circadian regulation. The book demonstrates advances and limitations of research on sphingolipid metabolism and its roles in metabolic diseases and other diseases. It offers graduate students and researchers a coherent overview of sphingolipids, as well as the limitations of current research in the field, and promotes further studies on metabolic diseases, as well as pharmaceutical research on drug discovery based on sphingolipid de novo synthase.